- Home
- FUL vs KNSA Comparison
FUL vs KNSA Comparison
Compare FUL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUL
- KNSA
- Stock Information
- Founded
- FUL 1887
- KNSA 2015
- Country
- FUL United States
- KNSA United Kingdom
- Employees
- FUL N/A
- KNSA N/A
- Industry
- FUL Home Furnishings
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- FUL Industrials
- KNSA Health Care
- Exchange
- FUL Nasdaq
- KNSA Nasdaq
- Market Cap
- FUL 3.2B
- KNSA 2.6B
- IPO Year
- FUL N/A
- KNSA 2018
- Fundamental
- Price
- FUL $59.23
- KNSA $38.86
- Analyst Decision
- FUL Buy
- KNSA Strong Buy
- Analyst Count
- FUL 5
- KNSA 7
- Target Price
- FUL $68.60
- KNSA $45.43
- AVG Volume (30 Days)
- FUL 413.4K
- KNSA 402.9K
- Earning Date
- FUL 09-24-2025
- KNSA 10-28-2025
- Dividend Yield
- FUL 1.58%
- KNSA N/A
- EPS Growth
- FUL N/A
- KNSA N/A
- EPS
- FUL 2.07
- KNSA 0.07
- Revenue
- FUL $3,502,085,000.00
- KNSA $529,332,000.00
- Revenue This Year
- FUL N/A
- KNSA $37.21
- Revenue Next Year
- FUL $2.42
- KNSA $12.07
- P/E Ratio
- FUL $28.72
- KNSA $588.62
- Revenue Growth
- FUL N/A
- KNSA 56.18
- 52 Week Low
- FUL $47.56
- KNSA $17.82
- 52 Week High
- FUL $81.03
- KNSA $39.43
- Technical
- Relative Strength Index (RSI)
- FUL 49.60
- KNSA 63.05
- Support Level
- FUL $57.82
- KNSA $36.80
- Resistance Level
- FUL $60.54
- KNSA $39.41
- Average True Range (ATR)
- FUL 1.46
- KNSA 1.17
- MACD
- FUL 0.00
- KNSA -0.14
- Stochastic Oscillator
- FUL 65.16
- KNSA 86.35
About FUL H. B. Fuller Company
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.